Is Thymosin Alpha-1 Legal in Florida? How to Access It Legally
Key numbers
- 1.6 mgDose in the Italian Zadaxin label, which is not a US-approved doseSource: fda.gov, as cited Nov 7, 2026
- 10 randomized trialsRandomized trials pooled in the 2026 Cochrane review, which found uncertain benefitSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 4 yes and 17 noFDA advisory committee vote against adding thymosin alpha-1 to the state-licensed pharmacy listSource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA approval / None - no US application for thymosin alpha-1 [1]
- Orphan designations / Four in the US, which is not an approval [1]
- Approved abroad / Italy, India and Hong Kong; Zadaxin is the brand [1]
- FDA pharmacy list / In none of the three categories for state-licensed pharmacies [2]
- Advisory committee / 4 yes, 17 no on both the free base and the acetate, December 2024 [3]
- FDA safety concerns / Immunogenicity for certain routes, peptide impurities, inadequate safety data [4]
- HHS peptide draft / Not among the six peptides covered [5]
- WADA / Not named on the 2026 Prohibited List [6]
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for it, and FDA's December 2024 review notes four US orphan drug designations, which is a separate process from approval and not an approval [1].
It is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymus extract, and thymalfasin is the synthetic version with the same sequence. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US [1].
Some countries do license it. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
Can a US pharmacy compound it?
Federal compounding rules differ by type of facility. State-licensed pharmacies generally must compound on receipt of a valid patient-specific prescription to avoid FDA's approval requirements; outsourcing facilities may also fill orders that are not for an identified patient [7]. Thymosin alpha-1 appears in none of the three categories on FDA's list for state-licensed pharmacies; on the list for outsourcing facilities it is category 3, 'nominated without adequate support', and FDA's category 1 policy does not apply to it [2][8].
FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) lists it in the 'nominated but withdrawn' table: it had been in category 2 and came off when the nominators withdrew. The concerns FDA posted remain - 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [4].
On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate, and FDA proposed that it not be added to its list for state-licensed pharmacies [3]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].
Questions worth asking
What this means for Florida
There is no US-approved thymosin alpha-1 product, so there is no approved version to prescribe in Florida or anywhere else in the country [1]. No FDA or HHS action identified allows compounding it [5]. These federal findings do not establish a legal route to obtain it in Florida.
What does the label say, and does it work?
No US-approved dose exists. The Italian Zadaxin label says 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second, and says not for children and contraindicated in pregnancy and breastfeeding [1].
A 2026 Cochrane review pooled 10 randomized trials with 1,349 adults with chronic hepatitis B. It found uncertain benefits, with certainty varying by outcome, and the reviewers said they are 'not sure' thymosin alpha-1 helps [9].
Frequently asked questions
Is thymosin alpha-1 legal in Florida?
Can I get a compounded thymosin alpha-1 prescription?
Where is thymosin alpha-1 approved?
What dose of thymosin alpha-1 is used?
Is thymosin alpha-1 banned in sport?
What safety data exist for thymosin alpha-1?
References
Show all 9 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- World Anti-Doping Agency.
- Human Drug Compounding Laws | FDA.
- U.S. Food and Drug Administration.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.